Scinai files prospectus for resale of 2.7 million ADSs

0 min read | Published on 25 Sept 2026, 02:02 AM |Updated on 25 Sept 2026, 02:02 AM

Reviewed by

Shraddha JScanX News Team

Add as a preferred
source on Google

Key Highlights

Scinai Immunotherapeutics filed a prospectus for the resale of up to 2,706,450 ADSs
The selling shareholder is identified as YA II PN, Ltd.
Proceeds from the sale will go to the selling shareholder, not the company

*this image is generated using AI for illustrative purposes only.

Scinai Immunotherapeutics Ltd. filed a prospectus for the resale of up to 2,706,450 American Depositary Shares (ADSs). The offering involves shares held by YA II PN, Ltd., indicating a secondary market transaction rather than new capital raising for the company.

The filing outlines the terms for the distribution of these securities in the US markets. As a resale prospectus, the proceeds from the sale of these ADSs will accrue to the selling shareholder, YA II PN, Ltd., and not to Scinai Immunotherapeutics.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the potential dilution from YA II PN's resale impact Scinai's future ability to raise primary capital?

What are the current clinical pipeline milestones for Scinai that could influence investor sentiment during this secondary offering?

Is there a pattern of increasing institutional selling by YA II PN that suggests a broader exit strategy from the biotech sector?

Scinai Immunotherapeutics Regains Nasdaq Compliance After Bid Price Recovery

0 min read | Published on 21 Sept 2026, 04:50 PM |Updated on 21 Sept 2026, 04:50 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Scinai Immunotherapeutics regained compliance with Nasdaq Listing Rule 5550(a)(2)
The company maintained a closing bid price of at least $1.00 for 19 consecutive business days
Nasdaq confirmed the minimum bid price matter is now closed
The firm operates as both a biopharma developer and a contract manufacturing organization

*this image is generated using AI for illustrative purposes only.

Scinai Immunotherapeutics Ltd has regained compliance with Nasdaq’s minimum bid price requirement, resolving a listing deficiency that had threatened its exchange status. The company confirmed receipt of written notification from Nasdaq Listing Qualifications on September 21, 2026, stating the matter is now closed.

The biopharmaceutical firm, which operates both an immunology therapeutic development pipeline and a revenue-generating contract development and manufacturing organization (CDMO), satisfied the criteria under Nasdaq Listing Rule 5550(a)(2). The rule mandates a minimum bid price of $1.00.

Compliance Details

Scinai met the regulatory threshold by sustaining a closing bid price of at least $1.00 for 19 consecutive business days. This sustained period of trading above the minimum threshold triggered the automatic reinstatement of compliance status without the need for a hearing or further appeal process.

The resolution of this matter removes immediate delisting risk for the Jerusalem-based company. Investors and stakeholders can now focus on the firm’s operational metrics, including its CDMO revenue streams and clinical trial progress, without the overlay of regulatory uncertainty regarding its exchange listing.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the removal of delisting risk influence institutional investor confidence and future capital raising efforts for Scinai?

What specific milestones in Scinai's immunology therapeutic pipeline are expected to drive revenue growth in the next fiscal year?

How does Scinai's CDMO segment performance compare to industry peers, and is it sufficient to sustain operations independent of clinical trial successes?